• Users Online: 256
  • Print this page
  • Email this page
Year : 2021  |  Volume : 7  |  Issue : 1  |  Page : 2-5

Management of dyslipidemia in chronic kidney disease

Department of Nephrology, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India

Correspondence Address:
Prit Pal Singh
Room No: 14, Department of Nephrology, Old Administrative Block, Indira Gandhi Institute of Medical Sciences, Sheikhpura, Patna - 800 014, Bihar
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jigims.jigims_6_20

Rights and Permissions

Dyslipidemia is one of the most important modifiable risk factors for cardiovascular morbidity and mortality in chronic kidney disease (CKD) patients. Lipid profile in CKD differs from that in general population. Even at normal or near-normal lipid levels, subparticles are more atherogenic and more pro-inflammatory. Because of altered clearance and metabolism of various lipid-lowering agents in CKD, its safety on long-term use remains a serious concern. Statins and ezetimibe remain drug of choice for most of the patients. The lowest and the safest dose of the drugs is guided by various trials. Until recently, not much study was available to formulate a guideline for these patients. However, recent studies and meta-analysis have solved this problem to some extent and that's evident with latest guidelines published by KDIGO and ACC/AHA.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded115    
    Comments [Add]    
    Cited by others 1    

Recommend this journal